Efficacy of Voriconazole in Treatment of Murine Pulmonary Blastomycosis†

AUTOR(ES)

Sugar, Alan M.

FONTE

American Society for Microbiology

RESUMO

We evaluated the efficacy of voriconazole, a new broad-spectrum triazole antifungal compound, in the treatment of murine pulmonary blastomycosis. Since mice metabolize voriconazole rapidly, we took advantage of our previous observation that administration of grapefruit juice to mice resulted in suitable serum voriconazole concentrations so that treatment studies with mice could be done (A. M. Sugar and X.-P. Liu, Med. Mycol. 38:209–121, 2000). Our results show that voriconazole prolonged survival in a dose-dependent fashion and that the fungal burden in the lungs was decreased by voriconazole administered at 40 mg/kg of body weight/day. Voriconazole should be studied in humans with blastomycosis.

Documentos Relacionados

• SCH 39304 in the treatment of acute or established murine pulmonary blastomycosis.
• Efficacy of nikkomycin Z against experimental pulmonary blastomycosis.
• Treatment of murine pulmonary blastomycosis with SCH 39304, a new triazole antifungal agent.
• Treatment of murine pulmonary blastomycosis with SCH 51048, a broad-spectrum triazole antifungal agent.
• Efficacy of Voriconazole in Treatment of Systemic Scedosporiosis in Neutropenic Mice